SG11202009680XA - Use of fubp1 inhibitors for treating hepatitis b virus infection - Google Patents
Use of fubp1 inhibitors for treating hepatitis b virus infectionInfo
- Publication number
- SG11202009680XA SG11202009680XA SG11202009680XA SG11202009680XA SG11202009680XA SG 11202009680X A SG11202009680X A SG 11202009680XA SG 11202009680X A SG11202009680X A SG 11202009680XA SG 11202009680X A SG11202009680X A SG 11202009680XA SG 11202009680X A SG11202009680X A SG 11202009680XA
- Authority
- SG
- Singapore
- Prior art keywords
- virus infection
- treating hepatitis
- fubp1
- inhibitors
- fubp1 inhibitors
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18165897 | 2018-04-05 | ||
PCT/EP2019/058664 WO2019193165A1 (en) | 2018-04-05 | 2019-04-05 | Use of fubp1 inhibitors for treating hepatitis b virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009680XA true SG11202009680XA (en) | 2020-10-29 |
Family
ID=61911421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009680XA SG11202009680XA (en) | 2018-04-05 | 2019-04-05 | Use of fubp1 inhibitors for treating hepatitis b virus infection |
Country Status (18)
Country | Link |
---|---|
US (2) | US11732262B2 (en) |
EP (1) | EP3775208A1 (en) |
JP (1) | JP7515400B2 (en) |
KR (1) | KR20200140853A (en) |
CN (1) | CN112055749A (en) |
AU (1) | AU2019247645A1 (en) |
BR (1) | BR112020020220A8 (en) |
CA (1) | CA3097544A1 (en) |
CL (1) | CL2020002563A1 (en) |
CR (1) | CR20200453A (en) |
IL (1) | IL277745A (en) |
MA (1) | MA52661A (en) |
MX (1) | MX2020010383A (en) |
PE (1) | PE20211912A1 (en) |
RU (1) | RU2020135289A (en) |
SG (1) | SG11202009680XA (en) |
TW (1) | TW202006138A (en) |
WO (1) | WO2019193165A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3097544A1 (en) | 2018-04-05 | 2019-10-10 | F. Hoffmann-La Roche Ag | Use of fubp1 inhibitors for treating hepatitis b virus infection |
CN114829599A (en) * | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Use of SCAMP3 inhibitors for treating hepatitis b virus infection |
AR122731A1 (en) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | IMPROVED OLIGONUCLEOTIDES TO MODULATE FUBP1 EXPRESSION |
EP4200419A2 (en) * | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
CN115851725B (en) * | 2022-10-28 | 2024-06-11 | 珠海市人民医院 | SiRNA for inhibiting expression of helicase V gene and application thereof |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1331011A3 (en) | 1991-10-24 | 2003-12-17 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5580760A (en) * | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
ID30093A (en) | 1999-02-12 | 2001-11-01 | Sankyo Co | NEW ANALOGUE OF NUCLEOSIDE AND OLIGONUKLEOTIDE |
ES2283298T3 (en) | 1999-05-04 | 2007-11-01 | Santaris Pharma A/S | ANALOGS OF L-RIBO-LNA. |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
JPWO2004027061A1 (en) | 2002-09-17 | 2006-01-19 | アステラス製薬株式会社 | Screening method for therapeutic drugs for antiproliferative diseases |
DK2284269T3 (en) | 2002-11-18 | 2017-10-23 | Roche Innovation Ct Copenhagen As | Antisense design |
CN1836042A (en) | 2003-06-12 | 2006-09-20 | 原子核物理公司 | Conserved HBV and HCV sequences useful for gene silencing |
JPWO2005116204A1 (en) * | 2004-05-11 | 2008-06-19 | 株式会社アルファジェン | Polynucleotide causing RNA interference and method for suppressing gene expression using the same |
WO2006082053A1 (en) | 2005-02-02 | 2006-08-10 | Heidelberg Pharma Gmbh | 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
AU2007211080B9 (en) | 2006-01-27 | 2012-05-03 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
AU2007257094B2 (en) | 2006-05-05 | 2012-10-25 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of SGLT2 |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
ES2376507T5 (en) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
WO2010080129A2 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011047312A1 (en) | 2009-10-16 | 2011-04-21 | Glaxo Group Limited | Hbv antisense inhibitors |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
KR101903778B1 (en) | 2010-10-28 | 2018-10-04 | 베니텍 바이오파마 리미티드 | Hbv treatment |
BR112013026306A2 (en) | 2011-04-20 | 2017-09-05 | Roche Glycart Ag | METHOD AND CONSTRUCTS FOR PASSING THE pH GRADE OF THE BLOOD-BRAIN BARRIER |
SI3505528T1 (en) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulation of hepatitis b virus (hbv) expression |
US8809293B2 (en) | 2011-06-30 | 2014-08-19 | Arrowhead Madison Inc. | Compositions and methods for inhibiting gene expression of hepatitis B virus |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
DK2751270T3 (en) | 2011-08-29 | 2018-10-29 | Ionis Pharmaceuticals Inc | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
EP2920304B1 (en) | 2012-11-15 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
FR2998748B1 (en) | 2012-11-23 | 2015-04-10 | Commissariat Energie Atomique | DEVICE AND METHOD FOR RETRANSMITTING DATA IN A NETWORK SWITCH |
EP2992098B1 (en) | 2013-05-01 | 2019-03-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating hbv and ttr expression |
SG10201908122XA (en) | 2013-06-27 | 2019-10-30 | Roche Innovation Ct Copenhagen As | Antisense oligomers and conjugates targeting pcsk9 |
JP2017505623A (en) | 2014-01-30 | 2017-02-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Poly-oligomer compound having biocleavable conjugate |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
SG11201702662UA (en) * | 2014-10-02 | 2017-04-27 | Protiva Biotherapeutics Inc | Compositions and methods for silencing hepatitis b virus gene expression |
WO2016055601A1 (en) | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US10975442B2 (en) * | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
CN105777770B (en) | 2014-12-26 | 2018-05-25 | 中国人民解放军第二军医大学 | A kind of the 7-Ethyl-10-hydroxycamptothecin compound and its long circulating liposome of saturated long chain fatty acid modification |
WO2016127002A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
US20170016000A1 (en) | 2015-07-17 | 2017-01-19 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
WO2017178656A1 (en) | 2016-04-14 | 2017-10-19 | Roche Innovation Center Copenhagen A/S | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE |
MA45496A (en) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION |
CA3097544A1 (en) | 2018-04-05 | 2019-10-10 | F. Hoffmann-La Roche Ag | Use of fubp1 inhibitors for treating hepatitis b virus infection |
-
2019
- 2019-04-05 CA CA3097544A patent/CA3097544A1/en active Pending
- 2019-04-05 PE PE2020001470A patent/PE20211912A1/en unknown
- 2019-04-05 EP EP19714455.3A patent/EP3775208A1/en active Pending
- 2019-04-05 JP JP2020554482A patent/JP7515400B2/en active Active
- 2019-04-05 SG SG11202009680XA patent/SG11202009680XA/en unknown
- 2019-04-05 KR KR1020207031603A patent/KR20200140853A/en active Search and Examination
- 2019-04-05 RU RU2020135289A patent/RU2020135289A/en unknown
- 2019-04-05 BR BR112020020220A patent/BR112020020220A8/en unknown
- 2019-04-05 WO PCT/EP2019/058664 patent/WO2019193165A1/en active Application Filing
- 2019-04-05 CR CR20200453A patent/CR20200453A/en unknown
- 2019-04-05 CN CN201980023565.2A patent/CN112055749A/en active Pending
- 2019-04-05 AU AU2019247645A patent/AU2019247645A1/en active Pending
- 2019-04-05 MA MA052661A patent/MA52661A/en unknown
- 2019-04-05 MX MX2020010383A patent/MX2020010383A/en unknown
- 2019-04-08 TW TW108112210A patent/TW202006138A/en unknown
-
2020
- 2020-10-01 IL IL277745A patent/IL277745A/en unknown
- 2020-10-02 CL CL2020002563A patent/CL2020002563A1/en unknown
- 2020-10-05 US US17/063,610 patent/US11732262B2/en active Active
-
2023
- 2023-06-23 US US18/340,054 patent/US20240150758A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020135289A (en) | 2022-05-05 |
PE20211912A1 (en) | 2021-09-28 |
CR20200453A (en) | 2021-03-02 |
US20210024934A1 (en) | 2021-01-28 |
BR112020020220A8 (en) | 2021-02-17 |
US11732262B2 (en) | 2023-08-22 |
CN112055749A (en) | 2020-12-08 |
MX2020010383A (en) | 2020-12-10 |
WO2019193165A1 (en) | 2019-10-10 |
CL2020002563A1 (en) | 2021-05-07 |
EP3775208A1 (en) | 2021-02-17 |
KR20200140853A (en) | 2020-12-16 |
IL277745A (en) | 2020-11-30 |
MA52661A (en) | 2021-02-17 |
JP7515400B2 (en) | 2024-07-12 |
JP2021520387A (en) | 2021-08-19 |
CA3097544A1 (en) | 2019-10-10 |
TW202006138A (en) | 2020-02-01 |
AU2019247645A1 (en) | 2020-10-15 |
BR112020020220A2 (en) | 2021-01-19 |
US20240150758A1 (en) | 2024-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257384A (en) | Rnai-containing compositions and use of same for treating hepatitis b virus infection | |
IL277745A (en) | Use of fubp1 inhibitors for treating hepatitis b virus infection | |
HRP20190352T1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
HK1251221A1 (en) | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection | |
EP3472362C0 (en) | Papd5 and papd7 inhibitors for treating an hepatitis b infection | |
HK1223931A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
IL280769A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
HUE054191T2 (en) | Treatment of hepatitis delta virus infection | |
ZA202100143B (en) | Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating rna virus infection | |
LT3137078T (en) | Treatment of hepatitis delta virus infection | |
IL279078A (en) | Combination therapy for treating hepatitis b virus infection | |
IL271491B1 (en) | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection | |
HK1254547A1 (en) | Anti-virus agent and method for treatment of viral infection | |
EP3894402C0 (en) | N-containing chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection | |
ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |